Want to see IN:MARKSANS full AI Analyst Report?
Marksans Pharma Limited (MARKSANS) Ratios
Marksans Pharma Limited Ratios
IN:MARKSANS's free cash flow for Q1 2027 was $0.00. For the 2027 fiscal year, IN:MARKSANS's free cash flow was increased by $0.00 and operating cash flow was $0.00. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 5.17 | 4.62 | 4.78 | 4.91 | 3.37 |
| Quick Ratio | 3.32 | 2.85 | 3.19 | 3.49 | 2.18 |
| Cash Ratio | 1.20 | 1.04 | 1.03 | 1.12 | 0.97 |
| Solvency Ratio | 0.64 | 0.62 | 0.65 | 0.75 | 0.55 |
| Operating Cash Flow Ratio | 0.91 | 0.43 | 0.59 | 0.70 | 0.28 |
| Short-Term Operating Cash Flow Coverage | 16.27 | 8.95 | 7.92 | 5.71 | 2.40 |
| Net Current Asset Value | $ 19.15B | $ 14.54B | $ 12.67B | $ 12.50B | $ 7.84B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.09 | 0.10 | 0.09 | 0.06 | 0.07 |
| Debt-to-Equity Ratio | 0.11 | 0.13 | 0.12 | 0.07 | 0.09 |
| Debt-to-Capital Ratio | 0.10 | 0.12 | 0.11 | 0.07 | 0.08 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.28 | 1.31 | 1.30 | 1.26 | 1.36 |
| Debt Service Coverage Ratio | 8.62 | 11.72 | 9.94 | 6.43 | 4.83 |
| Interest Coverage Ratio | 20.92 | 96.81 | 34.59 | 32.85 | 61.21 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 |
| Interest Debt Per Share | 8.11 | 7.36 | 5.63 | 3.18 | 2.91 |
| Net Debt to EBITDA | -0.48 | -0.33 | -0.31 | -0.65 | -0.78 |
| Profitability Margins | |||||
| Gross Profit Margin | 39.20% | 56.39% | 50.67% | 50.25% | 49.46% |
| EBIT Margin | 17.10% | 16.98% | 19.97% | 18.72% | 17.29% |
| EBITDA Margin | 20.45% | 20.16% | 23.38% | 21.52% | 20.32% |
| Operating Profit Margin | 17.10% | 43.04% | 17.80% | 16.19% | 34.93% |
| Pretax Profit Margin | 19.00% | 19.21% | 19.45% | 18.23% | 16.72% |
| Net Profit Margin | 14.16% | 14.51% | 14.41% | 14.38% | 12.47% |
| Continuous Operations Profit Margin | 14.23% | 14.59% | 14.46% | 14.33% | 12.62% |
| Net Income Per EBT | 74.55% | 75.52% | 74.07% | 78.87% | 74.57% |
| EBT Per EBIT | 111.05% | 44.65% | 109.30% | 112.62% | 47.88% |
| Return on Assets (ROA) | 10.82% | 11.75% | 11.70% | 12.16% | 11.25% |
| Return on Equity (ROE) | 13.82% | 15.43% | 15.19% | 15.26% | 15.35% |
| Return on Capital Employed (ROCE) | 15.14% | 40.86% | 16.91% | 16.21% | 40.27% |
| Return on Invested Capital (ROIC) | 11.10% | 30.38% | 12.29% | 12.36% | 28.84% |
| Return on Tangible Assets | 11.30% | 12.17% | 12.17% | 12.80% | 11.90% |
| Earnings Yield | 5.88% | 3.78% | 4.38% | 9.11% | 9.91% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.58 | 4.84 | 4.74 | 4.41 | 3.74 |
| Payables Turnover | 5.33 | 3.74 | 4.00 | 4.00 | 3.74 |
| Inventory Turnover | 1.85 | 1.35 | 1.74 | 1.90 | 1.76 |
| Fixed Asset Turnover | 3.14 | 2.93 | 3.14 | 4.79 | 4.32 |
| Asset Turnover | 0.76 | 0.81 | 0.81 | 0.85 | 0.90 |
| Working Capital Turnover Ratio | 1.50 | 1.64 | 1.55 | 1.70 | 2.04 |
| Cash Conversion Cycle | 208.98 | 247.72 | 195.76 | 183.40 | 207.16 |
| Days of Sales Outstanding | 79.73 | 75.45 | 76.93 | 82.73 | 97.68 |
| Days of Inventory Outstanding | 197.79 | 269.83 | 210.00 | 192.03 | 207.11 |
| Days of Payables Outstanding | 68.54 | 97.56 | 91.17 | 91.35 | 97.63 |
| Operating Cycle | 277.52 | 345.28 | 286.93 | 274.76 | 304.79 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 10.63 | 4.56 | 5.08 | 5.72 | 2.42 |
| Free Cash Flow Per Share | 7.75 | 0.74 | 0.48 | 4.42 | 1.29 |
| Dividend Paid and CapEx Coverage Ratio | 2.89 | 1.03 | 1.00 | 3.72 | 1.74 |
| Capital Expenditure Coverage Ratio | 3.69 | 1.20 | 1.10 | 4.43 | 2.14 |
| Operating Cash Flow Coverage Ratio | 1.40 | 0.64 | 0.94 | 1.93 | 0.90 |
| Operating Cash Flow to Sales Ratio | 0.16 | 0.08 | 0.11 | 0.13 | 0.07 |
| Free Cash Flow Yield | 4.94% | 0.34% | 0.30% | 6.28% | 2.84% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 17.02 | 26.42 | 22.83 | 10.98 | 10.09 |
| Price-to-Sales (P/S) Ratio | 2.41 | 3.83 | 3.29 | 1.58 | 1.26 |
| Price-to-Book (P/B) Ratio | 2.35 | 4.08 | 3.47 | 1.68 | 1.55 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 20.26 | 298.02 | 332.07 | 15.91 | 35.19 |
| Price-to-Operating Cash Flow Ratio | 14.77 | 48.66 | 31.09 | 12.32 | 18.76 |
| Price-to-Earnings Growth (PEG) Ratio | 1.74 | 1.24 | 2.87 | 0.26 | -0.45 |
| Enterprise Value Multiple | 11.30 | 18.69 | 13.76 | 6.69 | 5.41 |
| Enterprise Value | 68.20B | 98.83B | 70.03B | 26.65B | 16.27B |
| EV to EBITDA | 11.30 | 18.69 | 13.76 | 6.69 | 5.41 |
| EV to Sales | 2.31 | 3.77 | 3.22 | 1.44 | 1.10 |
| EV to Free Cash Flow | 19.43 | 292.87 | 324.69 | 14.50 | 30.74 |
| EV to Operating Cash Flow | 14.16 | 47.82 | 30.40 | 11.22 | 16.39 |
| Tangible Book Value Per Share | 63.78 | 52.44 | 43.71 | 39.86 | 27.71 |
| Shareholders’ Equity Per Share | 66.70 | 54.45 | 45.55 | 42.01 | 29.37 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.25 | 0.24 | 0.26 | 0.21 | 0.25 |
| Revenue Per Share | 65.11 | 57.89 | 48.03 | 44.59 | 36.16 |
| Net Income Per Share | 9.22 | 8.40 | 6.92 | 6.41 | 4.51 |
| Tax Burden | 0.75 | 0.76 | 0.74 | 0.79 | 0.75 |
| Interest Burden | 1.11 | 1.13 | 0.97 | 0.97 | 0.97 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 |
| SG&A to Revenue | 0.22 | 0.11 | 0.01 | 0.01 | 0.02 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.15 | 0.54 | 0.73 | 0.70 | 0.40 |
Currency in INR
